Cosentyx is a biologic drug used to treat psoriasis and psoriatic arthritis. It is a relatively new drug, having been approved by the FDA in 2015 [1]. Cosentyx is classified as an interleukin-17A (IL-17A) inhibitor, which works by blocking the action of IL-17A, a protein that plays a role in inflammation and the development of psoriasis and psoriatic arthritis [2].

Compared to other psoriasis treatments, Cosentyx has shown promising results in clinical trials. A study published in the Journal of Dermatological Treatment found that Cosentyx was more effective than etanercept, a commonly used biologic drug, in treating moderate-to-severe psoriasis [2]. Another study published in the Journal of the American Academy of Dermatology found that Cosentyx was more effective than ustekinumab, another biologic drug, in treating psoriasis [3].

In addition to its effectiveness, Cosentyx is also well-tolerated by patients. According to the drug's website, the most common side effects of Cosentyx are upper respiratory infections, diarrhea, and nausea [4]. However, these side effects are generally mild and do not require discontinuation of the drug.

Overall, Cosentyx appears to be a promising treatment option for psoriasis and psoriatic arthritis. While it may not be the right choice for every patient, it has shown to be effective in clinical trials and is generally well-tolerated by patients.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202001/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4970323/
[4] https://www.cosentyx.com/psoriatic-arthritis/faq